<SEC-DOCUMENT>0001193125-16-505242.txt : 20160315
<SEC-HEADER>0001193125-16-505242.hdr.sgml : 20160315
<ACCEPTANCE-DATETIME>20160315163334
ACCESSION NUMBER:		0001193125-16-505242
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160309
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160315
DATE AS OF CHANGE:		20160315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		161507328

	BUSINESS ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d163368d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Date of
earliest event reported) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;9, 2016 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO
PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-14888</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0969592</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S.&nbsp;Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification&nbsp;No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting, Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19462</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip&nbsp;Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (267) 440-4200 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Item&nbsp;5.02</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</U>. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;9, 2016, David B. Weiner, Ph.D., was appointed as a director of our company. In March 2016, Dr.&nbsp;Weiner joined the world
renowned Wistar Institute, the nation&#146;s first independent biomedical research facility and an international leader in cancer, immunology and infectious disease research, as Executive Vice President and Director of its Vaccine Center and the W.
W. Smith Endowed Chair in Cancer Research. On March&nbsp;1, 2016, Dr.&nbsp;Weiner retired as Professor, Department of Pathology&nbsp;&amp; Laboratory Medicine at the University of Pennsylvania and Chair of the Gene Therapy and Vaccine Program at the
University&#146;s Perelman School of Medicine. Dr.&nbsp;Weiner was employed by the University of Pennsylvania from 1986 until his retirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Weiner has served as chairman of our scientific advisory board since 2001, beginning with the predecessor company VGX
Pharmaceuticals. We have an exclusive license agreement to DNA-based immunotherapy and vaccine technology developed at the University of Pennsylvania. The technology was developed in the University of Pennsylvania laboratory of Dr.&nbsp;Weiner, who
is a pioneer in the field of DNA-based vaccines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;9, 2016, Dr.&nbsp;Weiner was granted a stock option to purchase 16,000
shares of our common stock at an exercise price of $7.02 per share and restricted stock units representing 16,000 shares of our common stock upon his appointment as a director. He was also granted stock option to purchase 30,000 shares of our common
stock at an exercise price of $7.02 per share and restricted stock units representing 30,000 shares of our common stock for consulting services as chair of our scientific advisory board. Dr.&nbsp;Weiner will also receive the same cash and equity
compensation that is paid to our other outside directors for their service as directors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Item&nbsp;9.01.</U></TD>
<TD ALIGN="left" VALIGN="top"><U>Financial Statements and Exhibits</U>. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:62.75pt; font-size:8pt; font-family:Times New Roman">Exhibit Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated March 10, 2016</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>INOVIO&nbsp;PHARMACEUTICALS,&nbsp;INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Peter Kies,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR></TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;15, 2016 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d163368dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g163368snap2.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I></I><B><I>NEWS RELEASE</I></B><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immediate Release </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investors:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101,&nbsp;<U>bhertel@inovio.com</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Media:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, <U>jrichardson@inovio.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals Appoints DNA Immunotherapy Pioneer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>David B. Weiner, Ph.D., to its Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, Pa. &#150; March&nbsp;11, 2016 &#150; Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that David B. Weiner, Ph.D., recognized in
scientific circles as the &#147;father of DNA vaccines and immunotherapies,&#148; has been appointed to Inovio&#146;s Board of Directors. Dr.&nbsp;Weiner was co-founder with J. Joseph Kim, Ph.D., Inovio&#146;s CEO, of VGX Pharmaceuticals in 2000;
via merger VGX later became Inovio Pharmaceuticals. Dr.&nbsp;Weiner will continue to serve as Chair of the company&#146;s Scientific Advisory Board, a position he has held since the formation of the company in 2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Weiner recently joined The Wistar Institute, the nation&#146;s first independent biomedical research institute, NCI-designated Cancer Center, and an
international leader in cancer, immunology and infectious disease research, as Executive Vice President, Director of its Vaccine Center, and the W. W. Smith Charitable Trust Endowed Professorship in Cancer Research. On March&nbsp;1, Dr.&nbsp;Weiner
retired as Emeritus Professor, Department of Pathology&nbsp;&amp; Laboratory Medicine at the University of Pennsylvania and Chair of the Gene Therapy and Vaccine Program at the University&#146;s Perelman School of Medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim, Inovio&#146;s President and CEO, said, &#147;Innovation is central to our company and its potential. While our board has deep
expertise in corporate development and product commercialization, a strategic perspective on key scientific and competitive trends is important to guide critical corporate strategy and investment decisions. David&#146;s achievements have recast how
we now think of vaccines &#150; as treatments and cures versus solely methods of disease prevention &#150; and significantly advanced the potential for paradigm-shifting immunotherapies. His knowledge and judgment will be invaluable to Inovio as we
continue to advance differentiated immunotherapy technology to become valuable medicines.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Weiner is a world-renowned leader in immunology
as well as gene vaccines and immunotherapy. He has more than 350 peer-reviewed publications in scientific journals, including mainstream scientific journals such as <I>Scientific American</I>, and has been designated by the Institute for Scientific
Information as one of the top-cited scientists in the world. An inventor of more than 100 issued and pending US patents, Dr.&nbsp;Weiner has received numerous honors including election as a fellow to the American Association for the Advancement of
Science in 2011 and the International Society for Vaccines in 2012. He was the recipient of the NIH Director&#146;s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World
Vaccine Congress. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children&#146;s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on
DNA vaccines for cancer immune therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Weiner holds a Ph.D. in developmental biology from the University of Cincinnati College of Medicine, an
M.S. in biology from the University of Cincinnati. and a B.S. in biology from SUNY at Stony Brook in Stony Brook, N.Y. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported
generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a
growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute,
U.S. Military HIV Research Program, and University of Manitoba. For more information, visit <U>www.inovio.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # # </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene
delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors,
including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results
achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100 and INO-3112, that pre-clinical studies and clinical trials may not
commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results
achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to
support our broad pipeline of SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, the ability of our
collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability
of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope
to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them
will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity
and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company&#146;s technology by potential corporate or other
partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2014, our Form 10-Q for the quarter ended
September&nbsp;30, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio&#146;s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive
of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g163368snap2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g163368snap2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M3+1[J\E$42]SW/H/4T 9^D>*-*UJ9H+29A,!G9(NTD>H]: -F@ H * "@ H
M* "@ H Y/Q]IEWJ&CQ-:HTGD2;WC7DD8QG'?% ''^#=)OI_$-M<+!)'#;MN=
MV4@=.GXT >N4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ')>
M/M,N]0T>%[5&D\B3<\:\DC&,X[XH Y'P9I-]-XAMKA8)(X;=MSNRD#IT_&@#
MUN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MHG"5G%\CV/8=1L8]2TZ>SE'R2H5^GH:\D]0\6@DN-"UM7(VSVDO(]<'D?B*
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M_GC^E '3T <E\10/^$:4^DZ_R- &)\,_^/\ OQ_TS7^= '=ZM?#3-'O+T_\
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M%?2$\M.RCZ X'\J /9[&U2RL+>UC&$B0*/P% %B@ H XWXC6B2:)!=8^>&4
M'V(Y_D* ,SX9W#"XO[;/RE5DQ[@X_K0!Z+0!SWC?_D4KS_@/_H0H XSX=?\
M(QR?]>[?S% 'JE 'EOQ&_P"1BA_Z]U_F: .O\#?\BG:?5_\ T(T ='0!R7Q$
M_P"197_KNG\C0!B?#3_C_O\ _KFO\Z .K\9(TOA'4HUZM"0*TI/EFGYD5%>#
M1\W1,$E1FZ*P)KZ!JZL>"M&?4UAY9L+<Q$&,QJ5(]"*^;:L['T*=RQ0 4 %
M'%_%#5?[-\'2PJ#YEXPA!]!U)_(?K75A(<U5/L<V*GR4WYGA^DVC7VJVMLHS
MOD&?IGFO6JSY(.1Y=*'/-(^G[==EM$I[*!7SQ[I2U[2UUC1;BS(&]ERA]&'2
MF!Y-X?U)]#U^">3**K>7,/13P?R_I0 :_J+ZYK\T\>65W\N%?]D<#\^OXT >
MM:%IBZ/HUM9J!N1<N?5CR30!HT <[XX_Y%*[^J_^A"@#COAU_P C%)_UP;^8
MH ]3H \1\0V[V7B.^B(P1,6'T)R/YT >R:;>)?Z;;7<9!66,-]#W% %J@ H
MXKXCWJ1Z1;V8(\R:7=CV7_ZY% %'X9VS>;?W1'R@+&#[]3_2@#T.@#GO&_\
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M\!:3]NUO[7(N8;0;OJYZ?XT >K4 % '.^./^12N_JO\ Z$* ..^'7_(Q2?\
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MC6=,&STFVS_'(YX_ ,:Q<<*OM-FJEB'T2+-O#J>M.!JFI3:E_P!.UNODV_\
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M4_YOP#FJ?R_B']I>(_\ H78?_ \?_$T<E/\ F_ .:I_+^(?VEXC_ .A=A_\
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MSFH1WW_"76-M%J]U%;7$4LK1*$P"A3 !*YQ\QS0!TM &-X?OKB]_M3[1)O\
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M,T'GGRBS<GY?K0!L4 8<WA33IIY69KD6\TGFRVJS$0R-G))7W/)'0]Q0!N4
M5I+""74;>^8'SX$=$.> &QGC_@(H LT 5;+3[?3_ +1]G!'VB9IWR<Y9NO\
M*@ U#3K75+0VUW%OCR&&"058<A@1R"/44 0:?HZ:?,TOVV]N7*[1]HG+A1[#
MI^/6@"S?V<6HV$]E.7$4Z%'V-M.#U&1TH KW&BV%Q%;1F!8Q;2))"8OE*%>F
M,=L<8]": -"@#,T[0X-+N[B>WN+DK.[2-"\NZ-69MQ(';F@"W>V<&H64MI<J
M6AE7:P#%3^!'(- %73=$M]-GEN%EN+FYD4(TUQ*7?:,X4>@R2>/6@#2H __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
